GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Goodwill-to-Asset

Meridian Bioscience (Meridian Bioscience) Goodwill-to-Asset : 0.25 (As of Sep. 2022)


View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Meridian Bioscience's Goodwill for the quarter that ended in Sep. 2022 was $116.3 Mil. Meridian Bioscience's Total Assets for the quarter that ended in Sep. 2022 was $463.1 Mil. Therefore, Meridian Bioscience's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 was 0.25.


Meridian Bioscience Goodwill-to-Asset Historical Data

The historical data trend for Meridian Bioscience's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Goodwill-to-Asset Chart

Meridian Bioscience Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Goodwill-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.27 0.28 0.26 0.25

Meridian Bioscience Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.26 0.25 0.24 0.25 0.25

Competitive Comparison of Meridian Bioscience's Goodwill-to-Asset

For the Diagnostics & Research subindustry, Meridian Bioscience's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meridian Bioscience's Goodwill-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Meridian Bioscience's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Meridian Bioscience's Goodwill-to-Asset falls into.



Meridian Bioscience Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Meridian Bioscience's Goodwill to Asset Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Goodwill to Asset (A: Sep. 2022 )=Goodwill/Total Assets
=116.3/463.097
=0.25

Meridian Bioscience's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Goodwill to Asset (Q: Sep. 2022 )=Goodwill/Total Assets
=116.3/463.097
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Meridian Bioscience  (NAS:VIVO) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Meridian Bioscience Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Meridian Bioscience (Meridian Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
3471 River Hills Drive, Cincinnati, OH, USA, 45244
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
Executives
Julie Diana Smith officer: Sr VP, Controller, PAO 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny director, officer: Chief Executive Officer 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller officer: EVP & CFO ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare officer: Interim CFO & Chief Acctg Off 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr. director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii director 807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna officer: Executive VP-Diagnostics 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams director C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini officer: Exec VP, Operations & IS 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen officer: EVP, Bus. Development/Strategy 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien officer: EVP, Life Science 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244

Meridian Bioscience (Meridian Bioscience) Headlines

From GuruFocus